Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022).
Katsarou, A. et al. Type 1 diabetes mellitus. Nat. Rev. Dis. Primers 3, 17016 (2017).
Mathieu, C., Martens, P. J. & Vangoitsenhoven, R. One hundred years of insulin therapy. Nat. Rev. Endocrinol. 17, 715–725 (2021).
Mitragotri, S., Burke, P. A. & Langer, R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655–672 (2014).
Geho, W. B. The importance of the liver in insulin replacement therapy in insulin-deficient diabetes. Diabetes 63, 1445–1447 (2014).
Brown, T. D., Whitehead, K. A. & Mitragotri, S. Materials for oral delivery of proteins and peptides. Nat. Rev. Mater. 5, 127–148 (2020).
Lee, J. S. et al. Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin. Nat. Biomed. Eng. 5, 983–997 (2021).
Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G. & Langer, R. Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 14, 45–57 (2015).
Lu, Y., Aimetti, A. A., Langer, R. & Gu, Z. Bioresponsive materials. Nat. Rev. Mater. 2, 16075 (2016).
Bakh, N. A. et al. Glucose-responsive insulin by molecular and physical design. Nat. Chem. 9, 937–944 (2017).
Wang, J. et al. Glucose-responsive insulin and delivery systems: innovation and translation. Adv. Mater. 32, 1902004 (2020).
Mo, R., Jiang, T., Di, J., Tai, W. & Gu, Z. Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem. Soc. Rev. 43, 3595–3629 (2014).
Wang, Z., Wang, J., Kahkoska, A. R., Buse, J. B. & Gu, Z. Developing insulin delivery devices with glucose responsiveness. Trends Pharmacol. Sci. 42, 31–44 (2021).
Gu, Z. et al. Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery. ACS Nano 7, 6758–6766 (2013).
Chen, Z. et al. Synthetic beta cells for fusion-mediated dynamic insulin secretion. Nat. Chem. Biol. 14, 86–93 (2018).
Podual, K., Doyle, F. J. & Peppas, N. A. Glucose-sensitivity of glucose oxidase-containing cationic copolymer hydrogels having poly(ethylene glycol) grafts. J. Control. Release 67, 9–17 (2000).
Kitano, S., Koyama, Y., Kataoka, K., Okano, T. & Sakurai, Y. A novel drug delivery system utilizing a glucose responsive polymer complex between poly (vinyl alcohol) and poly (N-vinyl-2-pyrrolidone) with a phenylboronic acid moiety. J. Control. Release 19, 161–170 (1992).
Hisamitsu, I., Kataoka, K., Okano, T. & Sakurai, Y. Glucose-responsive gel from phenylborate polymer and poly (vinyl alcohol): prompt response at physiological pH through the interaction of borate with amino group in the gel. Pharm. Res. 14, 289–293 (1997).
Matsumoto, A. et al. A synthetic approach toward a self-regulated insulin delivery system. Angew. Chem. Int. Ed. 51, 2124–2128 (2012).
Chou, D. H.-C. et al. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc. Natl Acad. Sci. USA 112, 2401–2406 (2015).
Wang, J. et al. Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs. Sci. Adv. 5, eaaw4357 (2019).
Yu, J. et al. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs. Nat. Biomed. Eng. 4, 499–506 (2020).
Wang, J. et al. Injectable biodegradable polymeric complex for glucose-responsive insulin delivery. ACS Nano 15, 4294–4304 (2021).
Matsumoto, A. et al. Synthetic ‘smart gel’ provides glucose-responsive insulin delivery in diabetic mice. Sci. Adv. 3, eaaq0723 (2017).
Zhang, J. et al. Week-long normoglycaemia in diabetic mice and minipigs via a subcutaneous dose of a glucose-responsive insulin complex. Nat. Biomed. Eng. (2023).
Brownlee, M. & Cerami, A. A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin. Science 206, 1190–1191 (1979).
Wang, J. et al. Glucose transporter inhibitor-conjugated insulin mitigates hypoglycemia. Proc. Natl Acad. Sci. USA 116, 10744–10748 (2019).
Yao, Y., Ji, K., Wang, Y., Gu, Z. & Wang, J. Materials and carriers development for glucose-responsive insulin. Acc. Mater. Res. 3, 960–970 (2022).
Chu, J. N. & Traverso, G. Foundations of gastrointestinal-based drug delivery and future developments. Nat. Rev. Gastroenterol. Hepatol. 19, 219–238 (2022).
Yang, T. et al. Ligand-switchable nanoparticles resembling viral surface for sequential drug delivery and improved oral insulin therapy. Nat. Commun. 13, 6649 (2022).
Xi, Z. et al. Dual-modified nanoparticles overcome sequential absorption barriers for oral insulin delivery. J. Control. Release 342, 1–13 (2022).
Drucker, D. J. Advances in oral peptide therapeutics. Nat. Rev. Drug Discov. 19, 277–289 (2020).
Yang, Y. et al. Recent advances in oral and transdermal protein delivery systems. Angew. Chem. Int. Ed. 62, e202214795 (2023).
Baryakova, T. H., Pogostin, B. H., Langer, R. & McHugh, K. J. Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nat. Rev. Drug Discov. 22, 387–409 (2023).
Lamson, N. G., Berger, A., Fein, K. C. & Whitehead, K. A. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability. Nat. Biomed. Eng. 4, 84–96 (2020).
Lagarrigue, P., Moncalvo, F. & Cellesi, F. Non-spherical polymeric nanocarriers for therapeutics: the effect of shape on biological systems and drug delivery properties. Pharmaceutics 15, 32 (2023).
Ji, K. et al. Material design for oral insulin delivery. Med X 1, 7 (2023).
Yu, J. et al. Glucose-responsive oral insulin delivery for postprandial glycemic regulation. Nano Res. 12, 1539–1545 (2019).
Wang, A. et al. Liver-target and glucose-responsive polymersomes toward mimicking endogenous insulin secretion with improved hepatic glucose utilization. Adv. Funct. Mater. 30, 1910168 (2020).
Xiao, Y. et al. Glucose-responsive oral insulin delivery platform for one treatment a day in diabetes. Matter 4, 3269–3285 (2021).
Han, X. et al. Zwitterionic micelles efficiently deliver oral insulin without opening tight junctions. Nat. Nanotechnol. 15, 605–614 (2020).
Lu, Y. et al. Micelles with ultralow critical micelle concentration as carriers for drug delivery. Nat. Biomed. Eng. 2, 318–325 (2018).
Banerjee, A., Qi, J., Gogoi, R., Wong, J. & Mitragotri, S. Role of nanoparticle size, shape and surface chemistry in oral drug delivery. J. Control. Release 238, 176–185 (2016).
Xiao, W. et al. Highly sensitive colorimetric detection of a variety of analytes via the Tyndall effect. Anal. Chem. 91, 15114–15122 (2019).
Cone, R. A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61, 75–85 (2009).
Pridgen, E. M. et al. Transepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery. Sci. Transl. Med. 5, 213ra167 (2013).
Acosta-Rodríguez, V. et al. Circadian alignment of early onset caloric restriction promotes longevity in male c57BL/6J mice. Science 376, 1192–1202 (2022).
Yang, R. et al. A glucose-responsive insulin therapy protects animals against hypoglycemia. JCI Insight 3, e97476 (2018).
Qiu, Y. et al. Long-lasting designer insulin with glucose-dependent solubility markedly reduces risk of hypoglycemia. Adv. Ther. (Weinh.) 2, 1900128 (2019).
Ayala, J. E. et al. Hyperinsulinemic–euglycemic clamps in conscious, unrestrained mice. J. Vis. Exp. 16, e3188 (2011).
Cao, Z., Zhang, L. & Jiang, S. Superhydrophilic zwitterionic polymers stabilize liposomes. Langmuir 28, 11625–11632 (2012).
Fan, W. et al. Mucus penetrating and cell-binding polyzwitterionic micelles as potent oral nanomedicine for cancer drug delivery. Adv. Mater. 34, 2109189 (2022).
Zou, J.-J. et al. Efficient oral insulin delivery enabled by transferrin-coated acid-resistant metal–organic framework nanoparticles. Sci. Adv. 8, eabm4677 (2022).
